Combining Motegrity (Prucalopride) and Linaclotide for Chronic Idiopathic Constipation or IBS-C

Guideline-Based Framework for Combination Therapy

• The American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) recommend both linaclotide and prucalopride as individual second-line agents for chronic idiopathic constipation (CIC) patients who fail over-the-counter laxatives, with a strong recommendation and moderate certainty 1, 2
• The Department of Veterans Affairs and Department of Defense (VA/DoD) guidelines suggest linaclotide for patients with IBS-C who do not respond to osmotic laxatives, though evidence for prucalopride in IBS-C is less robust in these guidelines 3, 4

Mechanistic Rationale for Combination

• Linaclotide and prucalopride have complementary mechanisms of action, with linaclotide increasing intestinal fluid secretion and prucalopride accelerating colonic transit, making combination therapy mechanistically reasonable 1, 2
• The combination of linaclotide and prucalopride may benefit patients with both slow transit and inadequate secretion, though no direct studies have evaluated this specific combination 1, 2

Practical Implementation Strategy

• The AGA-ACG guidelines recommend starting with monotherapy first, and then considering combination therapy with linaclotide and prucalopride if there is an inadequate response to either agent alone 1, 2

Safety Profile and Risk Management

• The combination of linaclotide and prucalopride requires close monitoring for additive diarrhea risk, especially in the first 1-2 weeks 7
• The recommended sequence for combination therapy is to start with linaclotide and then add prucalopride if there is an inadequate response, or to start with prucalopride and then add linaclotide 1, 2

Clinical Efficacy Expectations

• Linaclotide monotherapy increases complete spontaneous bowel movements by 1.37 per week and improves stool consistency, while prucalopride monotherapy softens stools and decreases straining 7
• Combination therapy with linaclotide and prucalopride may be most beneficial for patients with both slow transit and visceral hypersensitivity, or for partial responders to monotherapy 1, 2